Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kohli, Manish
Huang, Xiaoyi
Yuan, Tiezheng
Sun, Zhifu
Costello, Brian Addis
Quevedo, Fernando
Tan, Winston
Nandy, Debashis
Longenbach, Sherri
Wang, Liang
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Mayo Clin, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
260
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Mar, Nataliya
    Dwabe, Sami
    Baranda, Marlon N.
    Zarrabi, Kevin K.
    Eturi, Aditya
    Gulati, Shuchi
    Parikh, Mamta
    Seyedin, Steven N.
    Kalebasty, Arash Rezazadeh
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 217 - 223
  • [22] Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
    O'Leary-Kelly, Meghan
    Gao, Dexiang
    Weisdack, Sarah
    Lam, Elaine Tat
    Bernard, Brandon David
    Flaig, Thomas W.
    Kessler, Elizabeth Riley
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
    Marar, Mallika
    Long Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] Prognostic utility of FDG PET/CT in men with castrate-resistant metastatic prostate cancer
    Jadvar, Hossein
    Desai, Bhushan
    Ji, Lingyun
    Conti, Peter
    Dorff, Tanya
    Pinski, Jacek
    Quinn, David
    Groshen, Susan
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [25] Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
    Vaishampayan, Ulka N.
    Podgorski, Izabela
    Heilbrun, Lance K.
    Smith, Daryn W.
    Lawhorn-Crews, Jawana
    Dobson, Kimberlee
    Fontana, Joseph A.
    Heath, Elisabeth I.
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [26] Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
    Hyejung Lee
    Jincheng Shen
    Muhammad Zaki Fadlullah
    Anna Neibling
    Claire Hanson
    Enos Ampaw
    Tengda Lin
    Matt Larsen
    Jennifer Lloyd
    Benjamin L. Maughan
    Umang Swami
    Sumati Gupta
    Jonathan Tward
    Skyler B. Johnson
    Brock O’Neil
    Bogdana Schmidt
    Christopher B. Dechet
    Benjamin Haaland
    Liang Wang
    Aik-Choon Tan
    Manish Kohli
    Clinical Proteomics, 2025, 22 (1)
  • [27] A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric Jay
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel Peter
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    De Bono, Johann Sebastian
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Potential role of rituximab in metastatic castrate-resistant prostate cancer
    Bindal, Poorva
    Jalil, Sharif A. A.
    Holle, Lisa M.
    Clement, Jessica M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1509 - 1511
  • [29] Retreatment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone
    Leibowitz-Amit, Raya
    Alimohamed, Nimira
    Vera-Badillo, Francisco E.
    Seah, Jo-An
    Templeton, Arnoud J.
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    PROSTATE, 2014, 74 (14): : 1462 - 1464
  • [30] Next Generation Sequencing in metastatic castrate-resistant prostate cancer
    Adashek, Jacob J.
    Salgia, Meghan
    Pal, Sumanta K.
    UROLOGY CASE REPORTS, 2018, 19 : 60 - 62
12345